Vepdegestrant Improves PFS vs Fulvestrant in ESR1-Mutated, ER+/HER2– Advanced Breast Cancer

First Look With ASCO Daily News presents Dr. Erika Hamilton of the Sarah Cannon Research Institute on the results of the phase 3 VERITAC-2 trial that compared vepdegestrant versus fulvestrant for patients with ESR1-mutated, ER-positive/HER2-negative advanced breast cancer. Read the full abstract (LBA1000) from the 2025 ASCO Annual Meeting: https://meetings.asco.org/abstracts-presentations/244378 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 9, 2025_

Video Lainnya